Cholinesterase Inhibitors & Memantine

Acetylcholinesterase inhibitors (AChEIs) and memantine remain the pharmacologic cornerstones of symptomatic treatment for Alzheimer disease (AD). Developed from the cholinergic hypothesis — the observation that acetylcholine activity is selectively reduced in the brains of patients with AD, correlating with neuronal loss in the nucleus basalis of Meynert — these agents do not halt neurodegeneration but delay cognitive, functional, and behavioral decline across the disease spectrum. With the emergence of anti-amyloid disease-modifying therapies (lecanemab, donanemab), symptomatic treatments continue to play a critical and complementary role in the management of every patient with AD, from mild cognitive impairment through severe dementia.

Cholinergic Hypothesis and Rationale

The cholinergic hypothesis emerged from discoveries in the 1970s and 1980s that acetylcholine (ACh) activity was selectively depleted in the cortex and hippocampus of patients with AD. This deficit correlated with autopsy findings of neuronal loss in the nucleus basalis of Meynert, the primary source of cortical cholinergic innervation. Inhibition of the catabolic enzyme acetylcholinesterase (AChE) was hypothesized to increase synaptic ACh concentrations, thereby improving cognitive function. The first large-scale AChEI trial demonstrating significant treatment effects (tacrine) was published in 1992. Tacrine was subsequently withdrawn due to hepatotoxicity, but three successors — donepezil, rivastigmine, and galantamine — were approved and remain in widespread use.

Cholinesterase Inhibitors: Individual Agents

Donepezil

Donepezil is the most widely prescribed AChEI and is generally the best tolerated oral agent. It is a selective, reversible AChE inhibitor with a long half-life (~70 hours), allowing once-daily dosing. It is approved for mild, moderate, and severe AD in both oral and transdermal formulations.

• Standard dosing: Start 5 mg daily for ≥4 weeks, then increase to 10 mg daily
• High-dose formulation: 23 mg daily (alternative formulation with slower absorption and higher C_max) can be considered after ≥3 months of stable 10 mg dosing; it provides a small additional cognitive benefit on the ADAS-Cog but no added improvement on global function, with more frequent adverse effects
• Transdermal patch: 5 or 10 mg/day; changed every 7 days; useful for patients with swallowing difficulty or GI intolerance
• Orally dissolving tablet: Available with identical dosing for patients who have difficulty swallowing standard tablets
• Vivid dreams and insomnia: Can be reduced by administering the dose in the morning rather than at bedtime

Rivastigmine

Rivastigmine is unique among AChEIs because it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). BuChE activity increases as AD progresses and may partially compensate for declining AChE, making dual inhibition a potential advantage in later-stage disease. Rivastigmine has the highest rate of GI adverse effects among oral AChEIs, but the transdermal patch formulation markedly reduces these events to placebo-level frequencies.

• Oral dosing: Start 1.5 mg BID, titrate by 1.5 mg BID every 4 weeks to target of 3–6 mg BID
• Transdermal patch: Start 4.6 mg/day, titrate every 4 weeks to 9.5 mg/day and then 13.3 mg/day; the 13.3 mg/day patch is the only AChEI formulation specifically approved for severe AD
• Preferred in Lewy body dementia: Rivastigmine is FDA-approved for PDD and has the strongest evidence base among AChEIs for dementia with Lewy bodies, where cholinergic deficits are even more pronounced than in AD
• Hepatic metabolism: Rivastigmine undergoes hydrolysis at the enzyme site rather than hepatic CYP450 metabolism, making it the preferred agent in patients with hepatic impairment or complex polypharmacy

Galantamine

Galantamine has a dual mechanism of action: it is a competitive, reversible AChE inhibitor and an allosteric potentiating ligand at nicotinic acetylcholine receptors. This nicotinic modulation may enhance presynaptic ACh release and provide additional cognitive and attentional benefits beyond AChE inhibition alone, though clinical trials have not demonstrated superiority over other AChEIs. It is approved for mild-to-moderate AD only (not severe).

• Immediate-release: Start 4 mg BID, titrate monthly to 8–12 mg BID
• Extended-release capsule: Start 8 mg daily, titrate monthly to 16–24 mg daily (preferred for adherence)
• Hepatic metabolism: Metabolized by CYP2D6 and CYP3A4 — dose adjustment needed with strong CYP2D6/3A4 inhibitors (e.g., paroxetine, ketoconazole)

Comparison of Cholinesterase Inhibitors

Efficacy of Cholinesterase Inhibitors

Cognitive Outcomes

Across randomized, double-blind, placebo-controlled trials of up to 24 months, all three AChEIs demonstrated consistent cognitive benefits in mild-to-moderate AD with no clinically meaningful differences in efficacy among agents. The drug-placebo difference was typically 3–5 points on the 70-point ADAS-Cog over 6 months (baseline ~25), representing a 10–20% relative benefit. Importantly, the average observed benefit was a delay in decline rather than improvement from baseline. Studies comparing AChEI-treated patients with projected models of change suggest beneficial effects may be sustained through 3–5 years of continued treatment.

On the MMSE, donepezil-treated patients showed no decline for >1 year, while placebo-treated patients declined 2.5 points. In a more pragmatic 2-year trial (AD2000), donepezil provided a benefit of approximately 0.8 MMSE points versus placebo, even with a 6-week therapy interruption.

Functional and Behavioral Outcomes

Memantine: NMDA Receptor Antagonism

Memantine is the only FDA-approved NMDA (N-methyl-D-aspartate) glutamate receptor modulator for AD. It was approved in 2004 for moderate-to-severe AD. The exact mechanism of symptomatic benefit remains unclear, but it is hypothesized to reduce glutamate-mediated excitotoxicity by blocking pathological tonic activation of NMDA receptors while preserving physiological synaptic signaling. There is no evidence that memantine is neuroprotective or disease-modifying — the FDA label explicitly states it does not prevent or slow neurodegeneration.

Memantine Monotherapy Evidence

In its pivotal 28-week trial (Reisberg et al., NEJM 2003), memantine 20 mg daily resulted in less decline on the Severe Impairment Battery (SIB) and better global function versus placebo in moderate-to-severe AD (MMSE ≤14). A second trial in a similar population did not replicate these findings at endpoint, though some benefits were seen at earlier time points. Importantly:

• Open-label extension revealed diminishing benefits over 12 months of monotherapy
• Patients switched from placebo to memantine after 24 weeks did not catch up to those on continuous treatment at 48 weeks
• Meta-analysis of 411 patients with mild AD across three trials found no evidence of benefit
• No clinical trials demonstrate efficacy in MCI
• Memantine is well tolerated, with no adverse effects occurring more frequently than placebo

Combination Therapy: AChEI + Memantine

Memantine is most frequently prescribed as add-on therapy to an existing AChEI regimen. In the pivotal combination trial (Tariot et al., JAMA 2004), adding memantine to stable donepezil therapy in patients with moderate-to-severe AD (MMSE 5–14) stabilized cognitive scores and reduced decline compared with donepezil + placebo. The fixed-dose combination capsule (donepezil 10 mg / memantine ER 28 mg) was approved based on bioequivalence, not independent efficacy data.

Adverse Effects and Safety

Gastrointestinal Side Effects

GI disturbances — nausea, vomiting, anorexia, diarrhea, and weight loss — are the most common adverse effects of oral AChEIs. They are dose-dependent and occur more frequently with rapid dose escalation. The frequency reported in clinical trials likely overestimates rates seen in clinical practice, partly because longer titration intervals reduce adverse event rates.

• Donepezil: Best tolerated orally; GI events are usually mild and transient with standard titration
• Rivastigmine oral: Highest GI adverse effect rate among oral agents; up to 47% nausea in clinical trials
• Rivastigmine patch: GI side effect rates comparable to placebo — the IDEAL study showed no more frequent GI symptoms than placebo with transdermal delivery
• Galantamine: Intermediate GI tolerability; extended-release formulation may reduce nausea

Practical Prescribing

Titration and Initiation

Managing GI Side Effects

• Use slow titration schedules (longer intervals between dose increases reduce nausea and diarrhea)
• Administer with food to reduce GI discomfort
• Switch from oral rivastigmine to the transdermal patch — GI side effects drop to placebo levels
• If a patient is intolerant to one AChEI, switch to a different agent or formulation after adverse effects resolve
• Consider donepezil morning dosing to reduce insomnia and vivid dreams

Switching and Discontinuation

Switching Between AChEIs

There is no evidence that one AChEI provides superior efficacy to another for patients with mild or moderate AD, and no systematic data support adding a second AChEI to the first. Switching agents is warranted only for intolerance, not for perceived lack of efficacy. When switching, allow adverse effects to resolve before starting the new agent.

Discontinuation and Deprescribing

AChEIs in the Era of Anti-Amyloid Therapy

With the FDA approval of lecanemab (2023) and donanemab (2024) for early AD, symptomatic treatments remain essential components of the therapeutic plan. In clinical trials of anti-amyloid antibodies, participants continued AChEIs and/or memantine as background therapy. There is no evidence that AChEIs interact adversely with anti-amyloid monoclonal antibodies, and current appropriate use recommendations endorse their concurrent use.

• Anti-amyloid therapies target plaque pathology and slow decline by ~25–35% on the CDR-SB over 18 months
• AChEIs provide complementary symptomatic benefit across cognitive, behavioral, and functional domains
• Patients on anti-amyloid therapy will still require symptomatic treatment throughout the disease course
• True prevention of AD remains years to decades away; symptomatic therapy will be needed indefinitely

Summary: Choosing the Right Agent

References

1. Geldmacher DS. Treatment of Alzheimer disease. Continuum (Minneap Minn). 2024;30(6):1823-1844.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;2006(1):CD005593.
3. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211-225.
4. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
5. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
6. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489-495.
7. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105-2115.
8. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-22.
9. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease. Clin Ther. 2010;32(7):1234-1251.
10. Parsons C, Lim WY, Loy C, et al. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. 2021;2(2):CD009081.
11. Knorz AL, Quante A. Alzheimer's disease: efficacy of mono- and combination therapy. A systematic review. J Geriatr Psychiatry Neurol. 2022;35(4):475-486.
12. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154.
13. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357(14):1382-1392.
14. Truong C, Recto C, Lafont C, et al. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials. Neurology. 2022;99(20):e2313-e2325.
15. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991-998.
16. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc. 2009;57(11):1997-2003.
17. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867-873.
18. Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174-179.
19. Haake A, Nguyen K, Friedman L, Chakkaparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Saf. 2020;19(2):147-157.
20. Cummings JL, Geldmacher D, Farlow M, et al. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294-301.